Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
metabolic drugs
Biotech
Lilly pens $1.2B pact with Sanegene to target metabolic RNA meds
Lilly penned a research pact worth $1.2 billion biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi medicines at the correct tissue.
James Waldron
Nov 10, 2025 4:05am
Barinthus enters reverse merger with metabolic disease biotech
Sep 30, 2025 10:39am
Biomea cuts staff, drops leukemia asset in metabolic shift
May 5, 2025 6:59pm
Novo taps Photys for multi-molecule cardiometabolic collab
Dec 18, 2024 7:30am
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
Skye ends eye disease R&D after glaucoma drug's phase 2 fail
Jun 10, 2024 8:51am
